** Shares of biotech firm Chimerix CMRX.O rise 70.2% to $8.42 premarket
** Jazz Pharmaceuticals JAZZ.O will acquire Chimerix for about $935 million to gain access to its experimental drug to treat a rare brain tumor, the companies say
** JAZZ will pay $8.55 per Chimerix share in an all-cash deal, which is expected to close in Q2; represents around 72% premium to its Tuesday's closing price
** CMRX has risen 320% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.